Spring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.52 Per Share

Brokerages forecast that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will post ($0.52) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Spring Bank Pharmaceuticals’ earnings. Spring Bank Pharmaceuticals reported earnings of ($0.47) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 10.6%. The business is expected to report its next quarterly earnings report on Friday, April 27th.

On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($2.41) per share for the current fiscal year, with EPS estimates ranging from ($3.09) to ($2.11). For the next year, analysts anticipate that the firm will post earnings of ($2.51) per share, with EPS estimates ranging from ($3.09) to ($1.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Spring Bank Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.18.

SBPH has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $32.00 price target (up from $29.00) on shares of Spring Bank Pharmaceuticals in a research report on Wednesday, February 21st. ValuEngine upgraded Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $28.00.

SBPH traded down $0.75 on Tuesday, hitting $13.50. 27,491 shares of the company were exchanged, compared to its average volume of 33,616. Spring Bank Pharmaceuticals has a 12 month low of $7.95 and a 12 month high of $18.93. The firm has a market cap of $175.01, a price-to-earnings ratio of -7.22 and a beta of -0.35.

Several hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its position in shares of Spring Bank Pharmaceuticals by 26.2% in the 4th quarter. BVF Inc. IL now owns 823,474 shares of the company’s stock worth $11,076,000 after buying an additional 170,798 shares during the last quarter. AXA grew its position in shares of Spring Bank Pharmaceuticals by 7.6% in the 4th quarter. AXA now owns 266,585 shares of the company’s stock worth $3,583,000 after buying an additional 18,859 shares during the last quarter. Morse Asset Management Inc grew its position in shares of Spring Bank Pharmaceuticals by 18.4% in the 4th quarter. Morse Asset Management Inc now owns 146,875 shares of the company’s stock worth $1,821,000 after buying an additional 22,875 shares during the last quarter. Sectoral Asset Management Inc grew its position in shares of Spring Bank Pharmaceuticals by 9.7% in the 3rd quarter. Sectoral Asset Management Inc now owns 123,383 shares of the company’s stock worth $2,078,000 after buying an additional 10,883 shares during the last quarter. Finally, Vanguard Group Inc. bought a new stake in shares of Spring Bank Pharmaceuticals in the 2nd quarter worth approximately $794,000. Hedge funds and other institutional investors own 28.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3341404/spring-bank-pharmaceuticals-inc-sbph-expected-to-announce-earnings-of-0-52-per-share.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rentokil Initial  Stock Rating Lowered by Deutsche Bank
Rentokil Initial Stock Rating Lowered by Deutsche Bank
Nielsen  Stock Rating Upgraded by BMO Capital Markets
Nielsen Stock Rating Upgraded by BMO Capital Markets
Countryside Properties  Price Target Raised to GBX 410
Countryside Properties Price Target Raised to GBX 410
Randgold Resources  Given a $100.00 Price Target at Desjardins
Randgold Resources Given a $100.00 Price Target at Desjardins
The J.M. Smucker  Cut to “Sell” at Credit Suisse Group
The J.M. Smucker Cut to “Sell” at Credit Suisse Group
Sensient Technologies  Earning Somewhat Positive News Coverage, Study Finds
Sensient Technologies Earning Somewhat Positive News Coverage, Study Finds


Leave a Reply

© 2006-2018 Ticker Report. Google+.